Related Experiment Videos
Experience with Salmonella typhi Vi capsular polysaccharide vaccine
L Hessel1, H Debois, M Fletcher
1Pasteur Mérieux MSD, Lyon, France.
Summary
Typhoid fever is a global health threat, but the Salmonella typhi Vi polysaccharide vaccine offers consistent protection. This vaccine is safe, effective, and can be co-administered with other travel vaccines.
Area of Science:
- Immunology
- Vaccinology
- Infectious Diseases
Background:
- Typhoid fever causes millions of cases and deaths globally each year.
- Increasing antibiotic resistance in Salmonella typhi complicates treatment options.
- The Vi polysaccharide vaccine has been developed to combat this threat.
Purpose of the Study:
- To review the development and clinical experience of the Salmonella typhi Vi polysaccharide vaccine.
- To assess the immunogenicity, efficacy, and safety of the Vi vaccine.
- To evaluate the vaccine's compatibility with other travel vaccines.
Main Methods:
- Review of field experience and reported side effects since 1989.
- Analysis of immunogenicity and efficacy data from single intramuscular or deep subcutaneous injections.
- Assessment of co-administration studies with other common travel vaccines.
Main Results:
- The Vi vaccine demonstrates consistent immunogenicity and efficacy.
- Reported side effects are infrequent and mild.
- Simultaneous administration with other travel vaccines does not affect immunogenicity or tolerability.
Conclusions:
- The Salmonella typhi Vi polysaccharide vaccine is a safe and effective tool for preventing typhoid fever.
- The vaccine's ability to be co-administered enhances its utility for travelers.
- Continued use and monitoring of the Vi vaccine are important for global health.